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Abstract 
High throughput screening technology has allowed significant advances to be 
made in the discovery of lead agents for use in the pharmaceutical and 
agrichemical industries. However, economic and practical constraints have limited 
the use of this technology in the identification of bioactive microbes targeted at crop 
pests and diseases. Smaller scale targeted screening programmes have generally 
provided greater success in identifying microbial bioactivity. This paper describes a 
strategy for targeted selection of bioactive Trichoderma spp. Isolates are selected 
for biological characteristics that best match the biocontrol blueprint developed for 
the target pathogen and are then put through a series of standardised bioassays. 
This strategy provides a rapid and cost-effective means of identifying biocontrol 
agents with commercial potential. 
Keywords: bioactive microbes, biocontrol blueprint, high throughput screening, 
targeted screens, Trichoderma. 
Introduction 
When developing a drug, pesticide or biological control agent, a diversity of 
synthetic chemicals, natural products and microbes are filtered through screening 
programmes to identify a lead agent that will potentially control the disease of 
interest. Such screening programmes are usually initiated by selecting a target and 
then developing an assay to screen for activity against the target. Subsequently, 
screening takes place to identify lead agents and selected leads undergo further 
assessments, such as optimisation and toxicology trials (Campbell 1989; Carnero 
2006; Mishra et al. 2008). Depending on the use of the product, preclinical and 
clinical trials or greenhouse and field trials take place with the ultimate goal of 
commercialisation. The basic framework of a screening programme may be applied 
to various research fields, but the scale and methods can vary depending on the 
screening source, target of interest and available resources (Ward & Bernasconi 
1999). 
High throughput screening 
Screening of synthetic chemicals to identify active compounds for pharmaceutical 
and agrichemical development has been conducted by high throughput screening 
(HTS) (Janzen 1996; Ridley et al. 1998; Pereira & Williams 2007). High throughput 
screening is the random screening of large numbers of compounds to identify leads 
that express activity against a selected target (Janzen 1996; Harvey 2002; Mishra 
et al. 2008). Prior to the invention of HTS, traditional drug development 
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programmes screened 20 to 50 compounds a week, but the introduction of HTS 
allowed screening as many as 100,000 samples a week (Pereira & Williams 2007). 
Advances were made by using robotics to decrease labour, replacing test tubes 
with 96-well microtitre plates to miniaturise assays, and computerising data 
analysis to increase speed (Carnero 2006; Pereira & Williams 2007). High 
throughput screening capability has also improved by identifying molecular targets 
through genomics research and enriching screening collections through the 
adoption of combinatorial chemistry (Hertzberg & Pope 2000; Koehn & Carter 
2005; Carnero 2006). For example, in the pharmaceutical industry, the availability 
of the human genome sequence and information on biochemical pathways of 
human diseases allow screening to be focussed by targeting molecular structures 
(Ridley et al. 1998; Steinrucken & Hermann 2000) . In contrast, in the agrichemical 
industry, which has a global market of one tenth of pharmaceuticals (Ward & 
Bernasconi 1999), the diversity of hosts and limited molecular information on pests 
and diseases often necessitates the targeting of whole organisms thereby 
diminishing the effective use of HTS technologies (Ridley et al. 1998; Steinrucken 
& Hermann 2000; Tietjen et al. 2005). Despite the advances in technologies that 
allow screening of many compounds over a short period of time, HTS has a high 
attrition rate (Hertzberg & Pope 2000; Carnero 2006). It is estimated that one drug 
is produced for every 1,000,000 compounds whereas one agrichemical is produced 
for every 140,000 that are screened (McDougall 2003; Carnero 2006). An 
advantage in agrichemical development is the feasibility to test leads directly on 
plants at an early stage in comparison to clinical tests with pharmaceuticals (Ward 
& Bernasconi 1999; Tietjen et al. 2005). 
Natural products 
Natural products are another major source of active ingredient used in the 
pharmaceutical and agrichemical industries that can be found by HTS (Harvey 
2002). The discovery of penicillin from the fungus Penicillium nota tum is a well-
known example (Demain 2006). Natural products are considered a valuable 
screening source as they provide greater structural diversity than synthetic 
chemicals and contain compounds that have been selected by evolutionary 
pressures (Knight et al. 1997; Harvey 2002; Koehn & Carter 2005; Harvey 2007). 
However, in contrast to synthetic chemicals that can be produced in the laboratory, 
sources for natural product screening require sampling from the environment 
(Harvey 2002; Verkman 2004). A diversity of environments can be sampled, 
including the air, water sources, soil, plants and microbial culture collections (R. Hill , 
personal communication). In particular, the unexplored biodiversity in marine 
environments is increasingly searched for novel products (Harvey 2007; Lam 2007). 
From the collected samples, crude extracts that contain mixtures of compounds are 
derived for HTS (Koehn & Carter 2005; Harvey 2007). To follow up on a positive 
result, purification of the active compound from the crude extract is necessary 
(Koehn & Carter 2005; Harvey 2007). 
The success rate of natural products over synthetic chemicals is unclear, but some 
reports suggest a higher success rate with natural products (Harvey 2002; Berdy 
2005). At Sphinx Pharmaceuticals Corp., both natural products and combinatorial 
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chemistry compounds are screened, and an average screen tests 125,000 
compounds over 4 months (Janzen 1996). At Biodiscovery New Zealand Ltd., more 
than 10,000 samples are screened every year with an average of one sample out 
of every 10,000 leading to commercialisation (R. Hill, personal communication). 
Natural products can also be useful as templates to synthesise chemicals with 
similar structures (Harvey 2007). An example is the development of azoxystrobin 
fungicides from strobilurin, a fungicidal compound found in a few Basidiomycete 
fungi (Knight et al. 1997). Despite the fact that half of successful pharmaceuticals 
are derived from or inspired by natural products (Demain 2006), screening of 
natural products has decreased in the last 15 years (Harvey 2002; Koehn & Carter 
2005; Harvey 2007; Mishra et al. 2008). Reasons include the incompatibilities with 
highly automated technologies developed for screening synthetic chemicals 
(Rollinger et al. 2008), difficulties in accessing biological sources and complications 
with handling mixtures of compounds (Harvey 2002; Koehn & Carter 2005; Mishra 
et al. 2008). However, more recently, the importance of natural products is being 
revisited as they prove to be a valuable source in pharmaceutical and agrichemical 
development (Knight et al. 1997; Harvey 2002; Koehn & Carter 2005; Harvey 2007; 
Mishra et al. 2008). 
Microbial bioactivity 
In contrast to HTS of synthetic chemicals and natural products, smaller-scale 
targeted screening programmes are used to identify microbial bioactivity. Examples 
of such microbes include probiotics that improve human and animal health as well 
as biological control agents (BCAs) that suppress agricultural diseases (Campbell 
1989; Fuller 1989). Prior to screening, isolation of source microbes is necessary, 
similar to that required for sampling of natural products (Campbell 1989; 
Montesinos 2003) . However, unlike the diverse sampling of natural products, 
isolation of source microbes is usually more focused on ecological niches that 
demonstrate evidence of beneficial bioactivity associated with the host of interest 
(Campbell 1989; Montesinos 2003). For instance, common sources to screen for 
human probiotics come from human intestines and likewise, common sources to 
screen for BCAs for postharvest fruit diseases come from fruit (O'Sullivan 2001; 
Janisiewicz & Korsten 2002; Fravel 2005; Taqarort et al. 2008; Vinderola et al. 
2008). As microbial bioactivity can be employed through multiple modes of action 
(Campbell 1989; Howell 2003; Roberts & Lohrke 2003; Kesarcodi-Watson et al. 
2008), the target for microbial screening is usually not molecular but the whole 
disease-causing organism itself. Initial screening commonly consists of in vitro 
laboratory assays examining growth inhibition on agar plates (Campbell 1989, 
1994; Fravel 2005; Kesarcodi-Watson et al. 2008). Such tests are easy to conduct 
and clear to read, but do not always reflect in vivo performance (Campbell 1989, 
1994; Fravel 2005; Kesarcodi-Watson et al. 2008). Plate tests select for microbes 
with particular modes of actions, such as the production of inhibitory substances or 
lytic activity on a specific medium; therefore, microbes with modes of action that 
are not expressed on plate tests, such as the ability to induce host resistance or 
production of enzymes, may be overlooked (Campbell 1989; Kesarcodi-Watson et 
al. 2008). Thus, although time-consuming and costly, in vivo screening with the 
host plant or animal is essential (Campbell 1989, 1994; Kesarcodi-Watson et al. 
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2008). The scale of microbial screening is smaller than synthetic chemical or 
natural product screening (Campbell 1994), ranging from approximately 50 isolates 
to a few hundred isolates (Clarkson et al. 2002; Idris et al. 2007; Taqarort et al. 
2008; Vinderola et al. 2008; Missotten et al. 2009). For BCA development, it is 
estimated that approximately 1 % of the original microbe source is taken to field 
trials (Campbell 1989; Montesinos 2003). In comparison to the high attrition rate of 
HTS and high costs in pharmaceutical industries where developing a drug can cost 
US $802 million (DiMasi et al. 2003), attrition rates and costs for BCA development 
are lower (Andrews 1992; Campbell 1994). This allows smaller research groups to 
pursue BCA development as a niche area of research without having to make large 
investments into HTS technologies. 
Trichoderma case study 
As mentioned previously, one of the main strategies for selection of microbial BCAs 
has been to isolate strains from the same ecological niche as the pest/pathogen 
that is being targeted for control (Cook & Baker 1983). This was the strategy used 
by the Plant Disease Biocontrol Research Group at Lincoln University during the 
early stages of development of its biocontrol research programmes. For example, 
survival structures were used to bait microbes from soil that could parasitise 
selected pathogens such as Sclerotinia (Jones & Stewart 2000), and microbes 
were isolated from the phylloplane of grape leaves and flowers to test for their 
activity against Botrytis cinerea grey mould (Walter et al. 2006). Surprisingly, what 
was observed from numerous isolations of this nature was that Trichoderma spp 
could be routinely isolated from all of the different ecological niches (roots, soil, 
pathogen survival structures, leaves, fruit, internal plant tissues). This was 
expected for soil-based niches but not for above-ground niches since Trichoderma 
is a recognised soil-borne saprophyte. Trichoderma spp. have been isolated from a 
diverse range of plant species (monocots and dicots), from wide geographical 
sources and across a broad environmental range (Klein & Eveleigh 1998). From 
the literature there are 104 known species, many of which include reported 
biocontrol agents, of which several have been developed as commercial products 
(Stewart 2001). An important attribute that favours the use of Trichoderma species 
for biocontrol is their multiple modes of action with isolates reported to act via 
mycoparasitism, antibiosis, competition, induced resistance and plant growth 
promotion (Harman 2006; Vinale et al. 2008). This has led to our view that the 
Trichoderma genus possesses isolates with such broad ranging biological 
attributes that there is a high likelihood of finding one or more isolates active 
against all of the key target plant pathogens of interest. This is further supported by 
repeated observations showing that isolates of Trichoderma obtained from the soil 
can perform equally well as biocontrol agents on foliage/flowers and other above-
ground environments. 
On the basis of these observations, a decision was made to focus the group's 
biocontrol research primarily on the selection of bioactive Trichoderma spp. A 
large-scale isolation programme was established in 2003 to collect Trichoderma 
isolates from different regions, soil types and cropping systems from throughout NZ. 
The Trichobank™ culture collection currently houses> 1000 isolates representing 
Tar 
21 species and providel 
screening programme~ 
characterised the isol 
characteristics (temp, 
antibiosis, parasitism, 
This is an on-going prq 
characterised isolates tl 
When a biocontrol prog 
a set of draft technic 
developed based upon 
optimum models of actl 
is then compared with I 
collection and the best 
then put through a ser 
group to further identi\ 
identify competitive sap 
production by the test fi 
assay and a spore proo 
these assays and the c 
best-performing isolate! 
room pathogen challer 
variable pathogen chall 
conditions and with diffE 
At this stage in the ~ 
identified and technical 
set thresholds for field 
practices, spore prod~ 
viability, shelf life. The 
undergo intensive field 
commercial developme 
This targeted screeninl 
develop a biocontrol a~ 
selected from the Trich 
and tested in laborato~ 
al. 2006). Three isolati 
business partners, Ai 
hamatum 6SR4 was se 
to be highly competitiv~ 
sclerotial parasite of ~ 
formulation) into the ~ 
seedling drench prior ti 
Jle plant production 
~nthetic chemical or 
oximately 50 isolates 
2007; Taqarort et al. 
A development, it is 
Jrce is taken to field 
3 high attrition rate of 
>ping a drug can cost 
:or BCA development 
~r research groups to 
having to make large 
on of microbial BCAs 
3.S the pest/pathogen 
las the strategy used 
University during the 
.mmes. For example, 
that could parasitise 
2000), and microbes 
Ners to test for their 
6). Surprisingly, what 
hat Trichoderma spp 
:il niches (roots, soil, 
tissues). This was 
3S since Trichoderma 
, been isolated from a 
11 wide geographical 
:veleigh 1998). From 
ich include reported 
commercial products 
Trichoderma species 
s reported to act via 
e and plant growth 
to our view that the 
j ranging biological 
more isolates active 
:; further supported by 
Jbtained from the soil 
'ers and other above-
to focus the group's 
Trichoderma spp. A 
) collect Trichoderma 
IS from throughout NZ. 
isolates representing 
Targeted screening for microbial bioactivity 
21 species and provides the underlying microbial resource for the research group's 
screening programmes. Over the past decade, the group has progressively 
characterised the isolates held in the culture collection based upon growth 
characteristics (temp, pH range) and biological characteristics (competition, 
antibiosis, parasitism, rhizosphere competence, induced resistance capability). 
This is an on-going process with the ultimate goal of creating a database of fully 
characterised isolates that can be searched for targeted bioactivity. 
Biocontrol blueprint 
When a biocontrol programme commences at the Bio-Protection Research Centre, 
a set of draft technical specifications for the potential BCA, a blueprint, is 
developed based upon knowledge of the pathogen's lifecycle, environmental niche, 
optimum models of action and likely formulation/application strategy. The blueprint 
is then compared with information known on the isolates held in the Trichobank™ 
collection and the best 20-30 matches identified. These 'best bet' test microbes are 
then put through a series of standardised bioassays developed by the research 
group to further identify bioactivity. Tests include a necrotic leaf disc assay to 
identify competitive saprophytic behaviour, a dual culture assay to identify antibiotic 
production by the test microbe, a plant growth promotion assay, a mycoparasitism 
assay and a spore production assay. Threshold levels of activity are set for each of 
these assays and the comparative performance of test microbes assessed. The 10 
best-performing isolates are then selected for further testing in glasshouse/growth 
room pathogen challenge trials. These trials are repeated several times under 
variable pathogen challenge and/or BCA inoculum density, different environmental 
conditions and with different basic BCA formulations. 
At this stage in the biocontrol programme, a commercial business partner is 
identified and technical specifications for a prototype product are developed that 
set thresholds for field performance, compatibility with current crop management 
practices, spore production capability and quality assurance parameters, e.g. 
viability, shelf life. The best performing isolates (3-5) from the glasshouse trials 
undergo intensive field testing for 2 years and then the top candidate is selected for 
commercial development. 
Biocontrol successes 
This targeted screening strategy was used successfully by the research group to 
develop a biocontrol agent for Sclerotinia disease of lettuce. Fifteen isolates were 
selected from the Trichobank™ collection based upon relevant biological attributes 
and tested in laboratory and glasshouse trials over a 3-year period (Rabeendran et 
al. 2006). Three isolates were selected for field testing in collaboration with our 
business partners, Agrimm Technologies Ltd, and one isolate Trichoderma 
hamatum 6SR4 was selected for commercial development. This isolate was shown 
to be highly competitive in the soil environment and was an effective mycelial and 
sclerotial parasite of Sc/erotinia minor. When applied as a solid substrate (flake 
formulation) into the nursery potting mix at the rate of 2 kg/m3 followed by a 
seedling drench prior to transplanting at the rate of 100 g/50 litres, the biocontrol 
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agent gave 50-75% control of Sclerotinia disease, which was equal to or better 
than the standard fungicide treatment (Rabeendran et al. 2006). Two products 
Lettucemate ™ Flake and Lettucemate ™ WP were commercialised in 2005 for use 
in lettuce nurseries in NZ and Australia (www.vinevax.com). 
A similar strategy was used to develop Trichoderma atroviride LU132 as a 
botryticide on grapes. This isolate had been initially developed as a biocontrol 
agent for use against onion white rot disease. The biological attributes of the 
biocontrol agent identified in this system (nutrient competition , localised antibiosis 
(Stewart & McLean 2007)) were recognised as having value for application in other 
systems, in particular grapevines where the environmental conditions (pH, 
temperature) on the leaf surface were a good match for this isolate. Intensive field 
testing of the isolate validated this proposition and the product Sentinel@ was 
commercialised in 2006 for use against Botrytis on grapevines in NZ and an 
extension of the application to include tomatoes was approved in 2007 
(www.vinevax.com). Current programmes that are utilising this targeted selection 
and screening strategy include Rhizoctonia diseases of potato and Sclerotinia 
disease of brassicas. 
Conclusion 
It is impractical and uneconomic for small biocontrol research groups to be able to 
implement intensive high throughput screening systems to identify microbes with 
specified bioactivity. The use of a targeted approach to selection and screening 
allows researchers to effectively rationalise the use of limited resources and make 
rapid progress in the identification of microbes with commercial potential. This has 
reduced the average length of time taken from initial screening to identification of 
the prototype product from 8-10 years down to 5-6 years, thereby allowing greater 
investment of time and money in the development of improved formulations and 
extensive field testing. 
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